There were no significant differences in the levels of BACE-1, PSEN-1, 5-HT, Ca2+, Phospholipase A2 (PLA2), DPH and I-[4-(trimethylamino) phenyl]-6-phenyl-1,3,5, hexatriene (TMA-DPH), between AD patients and control subjects (Fig. 2). This evidence concerns the gene BACE1 and Alzheimer disease.